ImmuCell Corp
NASDAQ:ICCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ImmuCell Corp
Cash Equivalents
ImmuCell Corp
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ImmuCell Corp
NASDAQ:ICCC
|
Cash Equivalents
$3.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
9%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$5.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$10.6B
|
CAGR 3-Years
25%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$9.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$6.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
2%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$18.9B
|
CAGR 3-Years
82%
|
CAGR 5-Years
54%
|
CAGR 10-Years
37%
|
|
ImmuCell Corp
Glance View
ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 60 full-time employees. The firm is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. The company manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. The company expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens, as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The firm is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.
See Also
What is ImmuCell Corp's Cash Equivalents?
Cash Equivalents
3.8m
USD
Based on the financial report for Dec 31, 2025, ImmuCell Corp's Cash Equivalents amounts to 3.8m USD.
What is ImmuCell Corp's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
9%
Over the last year, the Cash Equivalents growth was 1%. The average annual Cash Equivalents growth rates for ImmuCell Corp have been -13% over the past three years , -11% over the past five years , and 9% over the past ten years .
